GLMD Overview

Key Data

  • Open $2.4600
  • Day Range 2.1500 - 2.4900
  • 52 Week Range 2.1500 - 6.2900
  • Market Cap $61.2M
  • Shares Outstanding 25.08M
  • Public Float 19.71M
  • Beta 0.98
  • Rev. per Employee N/A
  • P/E Ratio N/A
  • EPS -$1.3545
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 323.85K 04/30/21
  • % of Float Shorted 1.64%
  • Average Volume 426.46K

Performance

5 Day
  • -14.34%
1 Month
  • -28.62%
3 Month
  • -57.96%
YTD
  • -27.01%
1 Year
  • -55.31%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4 Full Ratings

Recent News

  • MarketWatch
  • Dow Jones

Galmed Pharmaceuticals stock price target cut to $6 from $10 at Maxim Group

May. 13, 2021 at 1:11 p.m. ET by Tomi Kilgore

Galmed Pharmaceuticals downgraded to neutral from buy at B. Riley FBR

May. 22, 2020 at 7:50 a.m. ET by Tomi Kilgore

Galmed Pharmaceuticals started at buy with $29 stock price target at Canaccord Genuity

Dec. 2, 2019 at 1:58 p.m. ET by Tomi Kilgore

Galmed Pharmaceuticals started at buy with $35 stock price target at Stifel Nicolaus

Jul. 13, 2018 at 7:26 a.m. ET by Tomi Kilgore

Stocks end modestly higher as investors await Fed rate decision

Jun. 12, 2018 at 4:27 p.m. ET by Mark DeCambre

Galmed Pharmaceuticals' stock rockets 161% after trial results support FDA marketing application

Jun. 12, 2018 at 8:36 a.m. ET by Tomi Kilgore

Madrigal Pharma shares skyrocket 145% on positive results for liver disease therapy

Jun. 3, 2018 at 11:35 a.m. ET by Emma Court

Galmed Pharmaceuticals downgraded to hold from buy at Maxim Group

Feb. 14, 2018 at 9:21 a.m. ET by Tomi Kilgore

Galmed Pharma's stock loses more than half its value after drug trial misses endpoint

Feb. 14, 2018 at 9:15 a.m. ET by Tomi Kilgore

Allergan is paying a stunning 500% premium to buy a clinical-stage biotech

Sep. 21, 2016 at 6:53 a.m. ET by Ciara Linnane

Galmed Pharmaceuticals stock price target cut to $9 from $24 at Maxim Group

Aug. 1, 2016 at 7:26 a.m. ET by Tomi Kilgore
Barron's

Two Picks Boosted by Intercept NASH Trial

May. 21, 2015 at 10:27 a.m. ET
  • Other News
  • Press Releases

Analysts Are Bullish on Top Healthcare Stocks: Galmed Pharmaceuticals (GLMD), BioMarin Pharmaceutical (BMRN)

Mar. 22, 2021 at 6:35 a.m. ET on SmarterAnalyst

Galmed Dips 2% On Larger-Than-Expected Quarterly Loss

Mar. 19, 2021 at 6:34 a.m. ET on TipRanks.com

Analysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD), ADC Therapeutics (ADCT) and Ortho Clinical Diagnostics Holdings (OCDX)

Mar. 19, 2021 at 6:25 a.m. ET on SmarterAnalyst

Analysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and ESSA Pharma (EPIX)

Mar. 18, 2021 at 4:45 p.m. ET on SmarterAnalyst

These 2 Penny Stocks Could Rack up Triple-Digit Gains, Say Analysts

Feb. 11, 2021 at 11:16 a.m. ET on TipRanks.com

Maxim Group Gives a Buy Rating to Galmed Pharmaceuticals (GLMD)

Jan. 28, 2021 at 7:40 a.m. ET on SmarterAnalyst

Galmed Pharmaceuticals (GLMD) Gets a Buy Rating from Raymond James

Jan. 28, 2021 at 4:07 a.m. ET on SmarterAnalyst

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jan. 27, 2021 at 6:05 a.m. ET on SmarterAnalyst

Galmed Pharmaceuticals (GLMD) Received its Third Buy in a Row

Dec. 17, 2020 at 4:35 p.m. ET on SmarterAnalyst

Galmed Pharmaceuticals (GLMD) Gets a Buy Rating from Canaccord Genuity

Nov. 25, 2020 at 6:26 a.m. ET on SmarterAnalyst

H.C. Wainwright Thinks Galmed Pharmaceuticals’ Stock is Going to Recover

Nov. 18, 2020 at 8:06 a.m. ET on SmarterAnalyst

Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study

Nov. 16, 2020 at 1:31 p.m. ET on Zacks.com

Maxim Group Thinks Galmed Pharmaceuticals’ Stock is Going to Recover

Nov. 13, 2020 at 11:45 a.m. ET on SmarterAnalyst

Analysts’ Top Healthcare Picks: Galmed Pharmaceuticals (GLMD), Sol-Gel Technologies (SLGL)

Nov. 12, 2020 at 4:37 p.m. ET on SmarterAnalyst

Intercept's (ICPT) Q3 Loss Wider Than Expected, Sales Beat

Nov. 10, 2020 at 10:34 a.m. ET on Zacks.com

Intercept (ICPT) Posts New Positive Results on NASH Drug

Aug. 28, 2020 at 12:45 p.m. ET on Zacks.com

Intercept's (ICPT) Q2 Earnings and Revenues Beat Estimates

Aug. 11, 2020 at 8:20 a.m. ET on Zacks.com

Intercept Slumps as the FDA Issues CRL to NASH Candidate

Jun. 30, 2020 at 10:29 a.m. ET on Zacks.com

How Galmed (GLMD) Stock Stands Out in a Strong Industry

Jun. 10, 2020 at 8:34 a.m. ET on Zacks.com

After Drug Failure, Genfit's Cupboard Is Nearly Bare

May. 14, 2020 at 3:31 p.m. ET on GuruFocus.com

Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Competitors

Name Chg % Market Cap
Evoke Pharma Inc. -21.64% $49.21M
Competitor Data Provided ByCapital Cube Logo